The longevity and anti-aging wave is expanding into the US pet industry, with many dog and cat owners willing to spend heavily on experimental treatments and products, from anti-aging drugs, peptides, and supplements to red light therapy, even though many approaches still lack clear scientific evidence. US pet spending is expected to hit a record 165 billion dollars this year, while the pet supplement market is valued at 2.9 billion dollars in 2025, and about 10 percent of pet owners buy supplements for senior pets or anti-aging products. Rapamycin, originally used to prevent organ rejection in humans, is being tested in dogs under the TRIAD program at Texas A&M University and the University of Washington, with a target of enrolling 580 dogs. Loyal Animal Health is studying LOY-002 for senior dogs and expects to launch it next year, while Elanco Animal Health invested 368 million dollars in research and development last year in its pet longevity business. Veterinarians warn that using drugs and products without supporting evidence can carry risks, especially when purchased from sources whose quality cannot be verified.
Elanco Animal HealthElanco's pet longevity R&D investment aligns with growing market demand for anti-aging pet products.
Loyal's LOY-002 for senior dogs is highlighted as a key product in the anti-aging pet trend.
